Targeting angiogenesis for the treatment of prostate cancer

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 4, 2012, Pages 365-376

  Antonarakis, Emmanuel S ^a   Carducci, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

angiogenesis; bevacizumab; cabozantinib; clinical trials; drug development; itraconazole; lenalidomide; prostate cancer; sunitinib; tasquinimod; vadimezan

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CABOZANTINIB; CEDIRANIB; DASATINIB; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ITRACONAZOLE; LENALIDOMIDE; MITOXANTRONE; PACLITAXEL; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SORAFENIB; SUNITINIB; TASQUINIMOD; TEMSIROLIMUS; THALIDOMIDE; VADIMEZAN;

ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG TOLERABILITY; DYSPHONIA; EPISTAXIS; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; IMMUNOMODULATION; INJECTION SITE PAIN; MALE; MUSCLE WEAKNESS; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATECTOMY; PROTEINURIA; PRURITUS; RASH; REVIEW; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859569827     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.668887     Document Type: Review

References (83)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36
2. Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011;364:2055-8
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971(21):1182-6
4. Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist 2011;16:45-50
5. Kelly WK, Halabi S, Carducci MA, et al. A randomized double-blinded placebo controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with castration-resistant prostate cancer (CALGB 90401). J Clin Oncol 2012; In press This is the pivotal Phase III trial of docetaxel with or without bevacizumab for men with metastatic castration-resistant prostate cancer.
6. Dror Michaelson M, Oudard S, Ou Y, et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone versus prednisone alone in men with progressive metastatic castration-resistant prostate cancer. J ClinOncol 2011;29(Suppl):abstract 4515 This is the pivotal Phase III trial of sunitinib for men with docetaxel-refractory metastatic castration-resistant prostate cancer.
7. Celgene will discontinue phase III Mainsail trial in castrate-resistant prostate cancer. Boudry, Switzerland: Celgene Corp. 2011. Available from: http://ir.celgene.com/phoenix.zhtml?c=111960&p=irolnewsArticle&ID= 1633148&highlight [Last accessed 27 February 2012]
8. Li Y, Cozzi PJ. Angiogenesis as a strategic target for prostate cancer therapy. Med Res Rev 2010;30:23-66
9. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17:1359-70
10. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307
11. Kluetz PG, Figg WD, Dahut WL. Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother 2010;11:233-47
12. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7:1932-6 (Pubitemid 32994827)
13. Sweeney P, Karashima T, Kim SJ, et al. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cellmatrix metalloproteinase type 9 production. Clin Cancer Res 2002;8:2714-24 (Pubitemid 34856361)
14. Reese DM, Fratesi P, Corry M, et al. A Phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J 2001;3:65-70 (Pubitemid 34169203)
15. Picus J, Halabi S, Kelly WK, et al. A Phase II study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 2011;117:526-33
16. Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a Phase 2 study. Eur Urol 2008;54:1089-96
17. Halabi S, Kelly WK, George DJ, et al. Comorbidities predict overall survival in men with metastatic castrate-resistant prostate cancer. J Clin Oncol 2011;29(Suppl):abstract 189
18. Chu QS. Aflibercept: an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009;9:263-71
19. Isambert N, Freyer G, Zanetta S, et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel in patients with advanced solid tumors: preliminary results. J Clin Oncol 2008;26(Suppl):abstract 3599
20. Sanofi-Aventis, Regeneron Pharmaceuticals. Aflibercept in Combination with Docetaxel in Metastatic Androgen Independent Prostate Cancer. ClinicalTrial.gov NCT00519285. Available from: http://clinicaltrials.gov/ct2/ show/NCT00519285?term=NCT00519285&rank=1
21. Tabernero J, Van Cutsem E, Lakomy R, et al. Results from VELOUR, a phase III study of aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer [abstract LBA6]. ECCO-ESMO European Multidisciplinary Congress; 2011
22. Takeuchi K, Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull 2011;34:1774-80
23. Dror Michaelson M, Regan MM, Oh WK, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009;20:913-20
24. Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castrate-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010;21:319-24
25. Zurita AJ, George DJ, Shore ND, et al. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase I/II clinical trial. Ann Oncol 2011;published online 5 august 2011; doi: 10.1093/annonc/mdr349
26. Steinbild S, Mross K, Frost A, et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007;97:1480-5 (Pubitemid 350175850)
27. Dahut WL, Scripture C, Posadas E, et al. A Phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008;14:209-14 (Pubitemid 351377997)
28. Aragon-Ching JB, Jain L, Gulley JL, et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009;103:1636-40
29. Yin JJ, Zhang L, Munasinghe J, et al. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. Cancer Res 2010;70:8662-73
30. Ryan CJ, Stadler WM, Roth B, et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer. Invest New Drugs 2007;25:445-51 (Pubitemid 47222908)
31. Adelberg D, Karakunnel J, Gulley J, et al. A phase II study of cediranib in post-docetaxel castration resistant prostate cancer [abstract 41]. ASCO Genitourinary Cancers Symposium; 2010
32. Princess Margaret Hospital, Canada, National Cancer Institute (NCI). Cediranib Maleate With or Without Dasatinib in Patients With Hormone-Resistant Prostate Cancer Resistant to Treatment With Docetaxel. ClinicalTrials.gov NCT01260688. Available from: http://clinicaltrials.gov/ct2/show/NCT01260688? term=NCT01260688&rank=1
33. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002;60:1113-17 (Pubitemid 35447590)
34. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1-26 (Pubitemid 40732764)
35. Verras M, Lee J, Xue H, et al. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007;67:967-75
36. Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010;70:10090-100
37. Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer: results from a phase II randomized discontinuation trial. J ClinOncol 2011;29(Suppl):abstract 4516 This is the first trial, to our knowledge, to test cabozantinib in men with metastatic castration-resistant prostate cancer, showing striking responses in bone metastases.
38. McKeage MJ. The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opin Investig Drugs 2008;17:23-9 (Pubitemid 351578208)
39. McKeage MJ, Kelland LR. 5,6-dimethylxanthenoine-4-acetic acid (DMXAA) clinical potential in combination with taxane-based chemotherapy. Am J Cancer 2006;5:155-62 (Pubitemid 46224435)
40. Pili R, Rosenthal MA, Mainwaring PN, et al. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 2010;16:2906-614
41. Ng SS, MacPherson GR, Gutschow M, et al. Antitumor effects of thalidomide analogs in human prostate cancerxenografts implanted in immunodeficient mice. Clin Cancer Res 2004;10:4192-7 (Pubitemid 38812500)
42. Li H, Raia V, Bertolini F, et al. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU Int 2008;101:884-8 (Pubitemid 351347717)
43. Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol 2008;27:111-35 (Pubitemid 351589822)
44. Galustian C, Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother 2009;10:125-33
45. Figg WD, Dahut W, Duray P, et al. A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888-93 (Pubitemid 32994822)
46. Drake MJ, Robson W, Mehta P, et al. An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 2003;88:822-7 (Pubitemid 36520866)
47. Dahut WL, Gulley JL, Arlen PM, et al. Randomized Phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532-9 (Pubitemid 41103740)
48. Figg W, Retter A, Steinberg S, Dahut W. In reply to: "Inhibition of angiogenesis: thalidomide or low-molecular-weight heparin?". J Clin Oncol 2005;23:2113-214
49. Ning YM, Gulley JL, Arlen PM, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:2070-6
50. Mitsiades CS, Mitsiades N. Lenalidomide. Curr Opin Investig Drugs 2005;5:635-47
51. Moss R, Mohile S, Shelton G, et al. A phase I open-label study using lenalidomide and docetaxel in androgen-independent prostate cancer [abstract 89]. ASCO Genitourinary Cancers Symposium; 2007
52. Dreicer R, Garcia J, Smith S, et al. Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer. J Clin Oncol 2007;25(Suppl):abstract 15515
53. Garcia JA, Triozzi P, Elson P, et al. Clinical activity of ketoconazole and lenalidomide in castrate progressive prostate carcinoma: preliminary results of a phase II trial. J Clin Oncol 2008;26(Suppl):abstract 5143
54. Mathew P, Tannir N, Tu SM, et al. A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol 2010;65:811-15
55. Celgene Corp. Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer (Mainsail). ClinicalTrials.gov. NCT00988208. Available from: http://clinicaltrials.gov/ct2/show/NCT00988208?term= NCT00988208&rank=1
56. Keizman D, Zahurak M, Sinibaldi V, et al. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a Phase I/II double-blinded, randomized study. Clin Cancer Res 2010;16:5269-76 This study showed that lenalidomide has activity in men with biochemically-recurrent prostate cancer after local therapy.
57. Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 2012;109:32-9
58. Zabransky DJ, Smith HA, Thoburn CJ, et al. Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate 2012;72:487-98
59. Isaacs JT, Pili R, Qian DZ, et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 2006;66:1768-78 (Pubitemid 44893902)
60. Bjork P, Bjork A, Vogl T, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via their binding to quinolinecarboxamides. PLoS Biol 2009;7:e97
61. Dalrymple SL, Becker RE, Isaacs JT. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and docetaxel without effecting serum PSA directly in human xenografts. Prostate 2007;67:790-7 (Pubitemid 46709447)
62. Bratt O, Haggman M, Ahlgren G, et al. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer 2009;101:1233-40
63. Pili R, Haggman M, Stadler WM, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011;29:4022-8 This study showed that oral tasquinimod has activity in men with chemotherapy- naïve metastatic castration-resistant prostate cancer.
64. Active Biotech AB. A Study of Tasquinimod in Men with Metastatic Castrate Resistant Prostate Cancer. ClinicalTrials.gov NCT01234311. Available from: http://clinicaltrials.gov/ct2/show/NCT01234311?term=NCT01234311&rank=1
65. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 2007;448:645-6 (Pubitemid 47236844)
66. Chong CR, Xu J, Lu J, et al. Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2007;2:263-70 (Pubitemid 47629214)
67. Aftab BT, Dobromilskaya I, Liu JO, Rudin CM. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res 2011;71:6764-72
68. Xu J, Dang Y, Ren YR, Liu JO. Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc Natl Acad Sci USA 2010;107:4764-9
69. Karhadkar SS, Bova GS, Abdallah N, et al. Hedgehog signaling in prostate regeneration, neoplasia and metastasis. Nature 2004;431:707-12 (Pubitemid 39382619)
70. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010;17:388-99
71. Antonarakis ES, Heath EI, Smith DC, et al. A non-comparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): a DOD/PCCTC trial.J Clin Oncol 2011;29(Suppl):abstract 4532 This study showed that high-dose itraconazole has activity in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.
72. Stanford University. Study of Itraconazole in Castration Resistant Prostate Cancer (CRPC) Post Docetaxel Chemotherapy. ClinicalTrials.gov NCT01450683. Available from: http://clinicaltrials.gov/ct2/show/NCT01450683? term=NCT01450683&rank=1
73. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59
74. Case Comprehensive Cancer Center. Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy. ClinicalTrials.gov NCT01083368. Available from: http://clinicaltrials.gov/ct2/show/NCT01083368?term=NCT01083368&rank=1
75. Dana-Farber Cancer Institute, Genentech, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Cancer Institute of New Jersey. Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy. ClinicalTrials.gov NCT00776594. Available from: http://clinicaltrials.gov/ct2/show/NCT00776594?term=NCT00776594&rank=1
76. University of California (Irvine), Sanofi-Aventis. Trial of Taxotere Plus Sunitinib on Newly Diagnosed, Hormone Refractory, Metastatic Prostate Cancer. ClinicalTrials.gov NCT00879619. Available from: http://clinicaltrials.gov/ct2/ show/NCT00879619?term=NCT00879619&rank=1
77. Duke University, Pfizer, Sanofi-Aventis. Multimodality Phase II Study in Prostate Cancer. ClinicalTrials.gov NCT00734851. Available from: http://clinicaltrials.gov/ct2/show/NCT00734851?term=NCT00734851&rank=1
78. Oncology Specialists, S.C. Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer. ClinicalTrials.gov NCT00414388. Available from: http://clinicaltrials.gov/ct2/show/NCT00414388? term=NCT00414388&rank=1
79. University of Pennsylvania, National Cancer Institute (NCI). Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy. ClinicalTrials.gov NCT00589420. Available from: http://clinicaltrials.gov/ct2/show/NCT00589420?term=NCT00589420&rank=1
80. Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI). Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy. ClinicalTrials.gov NCT00527124. Available from: http://clinicaltrials.gov/ct2/ show/NCT00527124?term=NCT00527124&rank=1
81. Smith DC. Exelixis. Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone. ClinicalTrials.gov NCT01428219. Available from: http://clinicaltrials.gov/ct2/show/NCT01428219?term=NCT01428219&rank=1
82. University of Pittsburgh, Ortho Biotech, Inc. Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC). ClinicalTrials.gov NCT00307294. Available from: http://clinicaltrials.gov/ct2/show/NCT00307294? term=NCT00307294&rank=1
83. National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC). A Phase II Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer. ClinicalTrials.gov NCT00942578. Available from: http://clinicaltrials. gov/ct2/show/NCT00942578?term=NCT00942578&rank=1